[Molecular genetic mechanisms of drug resistance in prostate cancer].
The major problem in prostate cancer treatment is the development of drug resistance and especially important, cross-resistance. The mechanisms of drug resistance, which are divided into ligand-dependent (requiring the presence of androgens in the cell) and independent (not requiring the presence of androgens) are reviewed. The mechanisms are mainly represented with mutations of the androgen receptor and expression of aberrant constitutively active splice variants, as well as up-regulation of genes involved in androgens synthesis.
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.|Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.|Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow, 119121, Russia.|gskrasnov@mail.ru.
G S
GS
Krasnov
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.|Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
A A
AA
Dmitriev
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
A F
AF
Sadritdinova
Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
N N
NN
Volchenko
Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
E N
EN
Slavnova
Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
T V
TV
Danilova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
A V
AV
Snezhkina
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
N V
NV
Melnikova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
M S
MS
Fedorova
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
V A
VA
Lakunina
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.
A A
AA
Belova
Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
K M
KM
Nyushko
Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
B Y
BY
Alekseev
Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
A D
AD
Kaprin
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991, Russia.|Herzen Moscow Cancer Research Institute, Ministry of Health of the Russian Federation, Moscow, 125284, Russia.
A V
AV
Kudryavtseva
D000728:Androgens / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018432:Drug Resistance, Multiple / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011467:Prostate / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D012326:RNA Splicing / Q000187:drug effects; D011944:Receptors, Androgen / Q000235:genetics / Q000378:metabolism
D000728:Androgens; D000970:Antineoplastic Agents; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt; D011944:Receptors, Androgen; C410798:AR protein, human
abiraterone; androgen receptor; androgens; drug resistance; enzalutamide; mutations; prostate cancer; splice variants